降低伤口渗出物中的炎症因子是乳腺癌术后患者伤口愈合的一种有希望的治疗方法。中药(tcm)治疗已被证明对术后期间氧化应激的最佳调节是有益且安全的。在目前的临床试验中,我们评估了一种有前途的中草药配方的有效性,三黄汤[shd(黄芪,大黄,还有姜黄,3:1:1;补充表1)],乳房切除术后伤口炎症反应。
该研究将30名符合纳入和排除标准的乳腺癌患者随机分为治疗组(n=15)或对照组(n=15)。治疗组患者接受液体shd,每天服用两次,有或没有食物。术前1天给予治疗,术后7天给予治疗。对照组的参与者按照与治疗组相同的时间表接受安慰剂。每个受试者测量的结果包括临床tcm和伤口炎症症状评分,每日和排液总量,和渗出液中炎症因子的水平[肿瘤坏死因子α(tnf-α),白细胞介素6(il-6),8(il-8),和2R(il-2R),人C反应蛋白(crp)]在术后2小时和第1、3和7天。
治疗组7天内引流液总量(572.20±93.95mL)明显低于对照组(700.40±107.38mL)。治疗组的tcm症状评分也较低(第7天:1.87±0.83vs.4.80±3.61,p=0.049),炎症症状评分(第7天:0.67±0.72vs.3.67±2.50,p=0.001)。tnf-α的水平,il-6,il-8,il-2R,shd处理后,引流液中的crp明显降低。
在接受乳腺癌手术的患者中,shd的围手术期治疗有效地减少了术后渗出物并改善了炎症症状。
Reducing inflammatory factors in wound exudate is a promising treatment approach for healing wounds in postsurgical breast cancer patients. Traditional Chinese Medicine (tcm) treatments have been shown to be beneficial and safe for optimal regulation of oxidative stress during the postoperative period. In the present clinical
trial, we evaluated the effectiveness of a promising Chinese herbal formula, San Huang decoction [shd (Radix astragali, Radix et rhizoma rhei, and Rhizoma curcuma longa, 3:1:1; supplemental Table 1)], on wound inflammatory response after mastectomy.
The
study randomized 30 patients with breast cancer who fulfilled the inclusion and exclusion criteria to either a treatment (n = 15) or a control group (n = 15). Patients in the treatment group received liquid shd, taken twice daily with or without food. Treatment was given for 1 day before surgery and for 7 days postoperatively. Participants in the control group received a placebo on the same schedule as the treatment group. Outcomes measured in every subject included clinical tcm and wound inflammation symptom scores, daily and total amounts of drainage fluid, and levels of inflammatory factors in the exudate [tumour necrosis factor α (tnf-α), interleukins 6 (il-6), 8 (il-8), and 2R (il-2R), human C-reactive protein (crp)] at 2 hours and on days 1, 3, and 7 postoperatively.
The total amount of drainage fluid over 7 days was significantly lower in the treatment group (572.20 ± 93.95 mL) than in the control group (700.40 ± 107.38 mL). The tcm symptom score was also lower in treatment group (day 7: 1.87 ± 0.83 vs. 4.80 ± 3.61, p = 0.049), as was the inflammatory symptom score (day 7: 0.67 ± 0.72 vs. 3.67 ± 2.50, p = 0.001). Levels of tnf-α, il-6, il-8, il-2R, and crp in drainage fluid were significantly lower with shd treatment.
Perioperative treatment with shd effectively lessened postoperative exudate and ameliorated inflammatory symptoms in patients who underwent surgery for breast cancer.